Free Trial
LON:PRTC

PureTech Health (PRTC) Share Price, News & Analysis

PureTech Health logo
GBX 129.20 +2.00 (+1.57%)
As of 12:46 PM Eastern

About PureTech Health Stock (LON:PRTC)

Key Stats

Today's Range
126
130.80
50-Day Range
121.60
144.40
52-Week Range
100.40
214
Volume
426,934 shs
Average Volume
784,574 shs
Market Capitalization
£388.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 455
Consensus Rating
Buy

Company Overview

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Receive PRTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.

PRTC Stock News Headlines

Trump’s true trade war strategy
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.
PureTech Health plc – American Depositary Shares trading resumes
PureTech Rejects Nordic Capital Takeover Proposal
See More Headlines

PRTC Stock Analysis - Frequently Asked Questions

PureTech Health's stock was trading at GBX 150.20 at the beginning of 2025. Since then, PRTC shares have decreased by 14.0% and is now trading at GBX 129.20.
View the best growth stocks for 2025 here
.

Shares of PRTC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that PureTech Health investors own include IQE (IQE), Royal Dutch Shell (RDSB), BP (BP), GSK (GSK), Hummingbird Resources (HUM), Plug Power (PLUG) and AstraZeneca (AZN).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:PRTC
CIK
N/A
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 455
High Stock Price Target
GBX 455
Low Stock Price Target
GBX 455
Potential Upside/Downside
+252.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£91.86 million
Net Margins
-17,620.94%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£521.32 thousand
Cash Flow
GBX 60.33 per share
Price / Cash Flow
2.14
Book Value
GBX 113.55 per share
Price / Book
1.14

Miscellaneous

Free Float
N/A
Market Cap
£388.09 million
Optionable
Not Optionable
Beta
1.02
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (LON:PRTC) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners